comprehensive -WSS

comprehensive

author：entertainment 2025-09-30 23:33:30 - browse：31846

An advisory committee to the Food and Drug Administration will convene on Tuesday to evaluate the benefits of renal denervation, a one-time surgical procedure that works to reduce blood pressure. The promise — and the potential market — is enormous, but the data on how well the procedure works remains contentious.

The committee will evaluate data from two companies vying for market approval: ReCor Medical, a startup owned by Japanese company Otsuka Medical Devices, and device giant Medtronic, both of which have made surgical systems to treat hypertension.

Data from an analysis of three randomized clinical trials of ReCor Medical’s device showed a modest decrease in blood pressure after two months compared to a control group that received a placebo procedure. Medtronic’s late-stage trial showed that renal denervation reduced hypertension when measuring blood pressure in the doctor’s office, but did not show a reduction in blood pressure when patients measured it at home over 24 hours. At-home blood pressure is considered the more accurate measure, as blood pressure levels tend to artificially rise with anxiety in the clinic. Neither study presented serious safety concerns.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Cherokee Nation medical school graduates its first class

WSS

WuXi Biologics execs register to lobby as Congress comes for the company

Pfizer, Moderna say biotech, pharma drug development is a sprint

What a koala virus tells us about the human genome

Cancer, immunology, HIV research ensnared in fetal tissue politics

Chinese researcher claims birth of first gene

CVS is willing to dump 10% of its Medicare Advantage members

Wikipedia

comprehensive

knowledge

Malaria cases in Florida and Texas: Here’s what you need to know

Why H5N1 bird flu is keeping the CDC's top flu scientist awake

How to save PrEP access — and even expand it

Chinese researcher claims birth of first gene

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Asbestos ban is immediate, but health effects will linger for decades

Hepatitis C has a cure — but many Americans still lack access to it

Yancopoulos of Regeneron works to expand Dupixent success

Drug repurposing or repositioning? The language matters

Boston hospital trains restaurant workers on naloxone for overdoses

Wikipedia

Pfizer, Moderna say biotech, pharma drug development is a sprint

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

Bring on the sabbaticals for nurses

Readout LOUD podcast, live from the STAT Breakthrough Summit East

Oak Street deal isn't the answer to health care's woes

knowledge

focus

entertainment

knowledge